← All trials
NCT02709720
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2016
- Primary completion
- Apr 1, 2020
- Completion date
- Apr 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 67
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Spanish Lung Cancer GroupLead sponsor
- Hospital Son EspasesOverall official - principal investigator
- OsakidetzaOverall official - principal investigator
- Hospital Universitario Virgen MacarenaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Hospital General Universitario de CastellónOverall official - principal investigator
- Miguel Hernández UniversityOverall official - principal investigator
- Hospital Clinico Lozano BlesaOverall official - principal investigator
- Basque Country UniversityOverall official - principal investigator
- Universidad Autonoma de MadridStudy chair
- Universidad Autonoma de MadridOverall official - principal investigator
- University AlicanteOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.